Oligonucleotide therapeutics offer tremendous potential to enable long-lasting treatment with a precision medicine approach.
Learn about how scientists with expertise in data science, chemistry, biology and physics accelerate the design-make-test-analyse (DMTA) cycle of drug discovery to ensure these therapies are optimised for efficacy and safety.
------------------------------------------------------------
Global site: www.astrazenec...
Careers site: careers.astraz...
Follow us:
Twitter: / astrazeneca
LinkedIn: / astrazeneca
Instagram: / astrazeneca
Facebook: / astrazeneca
6 сен 2024
